UPDATE: Bank of America Downgrades AstraZeneca to Underperform Following Recent Gain
Bank of America reduced its rating on AstraZeneca (NYSE: AZN) from Neutral to Underperform while maintaining its price objective at $49.50 a share.
Bank of America commented, "With shares up c10% since mid-year we now have only 6% upside to our PO of £31, the second lowest amongst EU majors. We recognise that AZN's dividend yield of c6.3% remains the highest in EU big-cap pharma, and at the top end of the historic average within the sector. However, the fundamental outlook remains poor (although well recognized) with a 14-17E sales CAGR of minus 5%, recent product launches (Brilinta and Bydureon) remain lackluster, and the late stage pipeline remains weak, in our opinion."
AstraZeneca closed at $46.42 on Friday.
Latest Ratings for AZN
|Dec 2016||Leerink Swann||Upgrades||Market Perform||Outperform|
|Sep 2016||PiperJaffray||Initiates Coverage on||Overweight|
|Sep 2016||Exane BNP Paribas||Downgrades||Outperform||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.